GO
Loading...

Enter multiple symbols separated by commas

Stocks Merck & Co Inc

More

  • Sept 2- The U.S. Food and Drug Administration approved Tesaro Inc's treatment for chemotherapy-induced nausea and vomiting in adults, the company said on Wednesday. The drug, known chemically as rolapitant, was approved in combination with other agents to prevent delayed nausea and vomiting associated with some forms of chemotherapy, Tesaro said.

  • The FDA said it had identified 33 cases of severe joint pain in patients taking a class of drugs known as DPP-4 inhibitors between Oct. 16, 2006, when the first one was approved, through Dec. 31, 2013. Five cases were reported with AstraZeneca Plc's Onglyza, two with Boehringer Ingelheim's Tradjenta, and one with Takeda Pharmaceutical's Nesina.

  • Traders work on the floor of the New York Stock Exchange.

    Stocks pared gains and closed mostly lower on Thursday.

  • Top analyst: 3 reasons to buy Merck right now Thursday, 13 Aug 2015 | 11:17 AM ET
    Merck employees walk past a Merck sign in front of the company's building in Summit, New Jersey.

    Alex Arfaei of BMO Capital Markets upgraded Merck to "outperform" Thursday morning in a note sent to clients.

  • Early movers: KSS, MRK, COTY, TSLA, MNST & more Thursday, 13 Aug 2015 | 8:12 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Traders work on the floor of the New York Stock Exchange.

    U.S. stocks closed off lows, recovering from sharp intraday declines as gains in energy offset earlier pressures from global growth concerns.

  • Pfizer Inc, which is lagging rivals in the lucrative field of cancer immunotherapies, has been the first to report early data of an "accelerator" treatment that targets a protein called 4-1 BB. Bristol-Myers Squibb Co is hot on Pfizer's heels with a handful of early-stage trials of its own 4-1 BB antibody. Holbrook Kohrt, a researcher from Stanford University...

  • UPDATE 2-Allergan reports better-than-expected revenue Thursday, 6 Aug 2015 | 9:33 AM ET

    Aug 6- Irish drugmaker Allergan Plc reported better-than-expected revenue for the first full quarter since the merger of Actavis and Allergan. Allergan, which changed its name from Actavis after the deal closed, said adding signature drugs like Botox and eye drops Restasis boosted branded products sales five-fold to $3.71 billion in the second quarter...

  • There's more to Merck's Ebola vaccine than money Friday, 31 Jul 2015 | 2:18 PM ET
    A file photo of an Ebola vaccine trial in Liberia last February.

    A vaccine being developed by Merck and NewLink was shown to be 100 percent effective, but does this mean they'll make big bucks?

  • Merck, NewLink's Ebola vaccine 100% effective Friday, 31 Jul 2015 | 8:13 AM ET
    A woman gets vaccinated on March 10, 2015 at a health center in Conakry during the first clinical trials of the VSV-EBOV vaccine against the Ebola virus. The World Health Organization (WHO) said on March 5 that clinical trials launched on March 7 in Guinea marked the last step before the vaccine is available on the market.

    An Ebola vaccine developed in record time has proved highly effective against the deadly virus in a large trial in Guinea.

  • Venezuela currency blues hit U.S. blue-chip companies Thursday, 30 Jul 2015 | 3:38 PM ET

    BOSTON, July 30- Venezuela's currency woes cut nearly $3 billion in profit at U.S. blue-chip companies during the second quarter and prompted Procter& Gamble Co to remove its operations in the South American country from its consolidated financial reports. More so-called deconsolidation moves and exits from Venezuela are likely to happen during the second...

  • July 29- Express Scripts Holding Co, the largest pharmacy benefit manager in the United States, on Wednesday said the cost of potent, newly approved cholesterol drugs could "wreak financial havoc" among its clients. Express Scripts, which administers drug benefits for employers and health plans and also runs large mail-order pharmacies, has been challenging...

  • July 29- Express Scripts Holding Co, the largest pharmacy benefit manager in the United States, on Wednesday said the cost of potent new cholesterol drugs called PCSK9 inhibitors could "wreak financial havoc" among its clients. U.S. regulators on Friday approved the first of the new medicines, Praluent from Regeneron Pharmaceuticals Inc and Sanofi SA.

  • Pharma earnings were a 'mixed bag': Expert Tuesday, 28 Jul 2015 | 8:22 PM ET
    Pharma earnings were a 'mixed bag': Expert

    Raghuram Selvaraju, managing director for equity research healthcare division at MLV & Co, discusses the quarterly results of pharmaceutical giants such as Pfizer and Merck & Co.

  • Merck expanding cancer drug pipeline: CEO Tuesday, 28 Jul 2015 | 9:20 AM ET
    Merck expanding cancer drug pipeline: CEO

    CNBC's Meg Tirrell talks with Merck CEO Ken Frazier about the company's lung cancer drug Keytruda, and other drugs in the pipeline. Also Frazier weighs in on M&A in the pharma space and pricing pressures.

  • Early movers: F, PFE, MRK, DD, WYN, DHI & more Tuesday, 28 Jul 2015 | 8:36 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Panda bear market

    U.S. stocks have some powerful negatives tugging at them, not the least of which are the Shanghai "panda bear" market and a global commodities rout.

  • Dissecting big pharma's numbers: Pro Tuesday, 28 Jul 2015 | 7:44 AM ET
    Dissecting big pharma's numbers: Pro

    Barbara Ryan, Clermont Partners, breaks down Pfizer and Merck's quarterly results and shares her outlook on the pharmaceutical sector.

  • Minefield for market with Fed, earnings, commodities Monday, 27 Jul 2015 | 8:08 AM ET
    An oil trader works on the floor of the New York Mercantile Exchange.

    The Fed meets next week, but a commodities meltdown and earnings season are adding to concerns about global growth and may steal some of its thunder.

  • What to expect from Merck & Pfizer tomorrow Monday, 27 Jul 2015 | 6:52 AM ET
    What to expect from Merck & Pfizer tomorrow

    CNBC's Dominic Chu reports on Kensho studies, looking at Merck and Pfizer's stock performances around quarterly reports.